Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A.

Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877.

2.

Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?

Kamanna VS, Kashyap ML.

Am J Cardiol. 2007 Dec 3;100(11 A):S53-61. Review.

PMID:
18047854
3.

Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.

Gaidarov I, Chen X, Anthony T, Maciejewski-Lenoir D, Liaw C, Unett DJ.

Cell Signal. 2013 Oct;25(10):2003-16. doi: 10.1016/j.cellsig.2013.06.008. Epub 2013 Jun 14.

PMID:
23770183
4.

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.

Benyó Z, Gille A, Kero J, Csiky M, Suchánková MC, Nüsing RM, Moers A, Pfeffer K, Offermanns S.

J Clin Invest. 2005 Dec;115(12):3634-40.

5.

Future of GPR109A agonists in the treatment of dyslipidaemia.

Wanders D, Judd RL.

Diabetes Obes Metab. 2011 Aug;13(8):685-91. doi: 10.1111/j.1463-1326.2011.01400.x. Review.

PMID:
21418500
6.

Niacin stimulates adiponectin secretion through the GPR109A receptor.

Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL.

Am J Physiol Endocrinol Metab. 2009 Mar;296(3):E549-58. doi: 10.1152/ajpendo.91004.2008. Epub 2009 Jan 13.

7.

beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.

Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJ.

J Clin Invest. 2009 May;119(5):1312-21. doi: 10.1172/JCI36806. Epub 2009 Apr 6.

8.

Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor.

Kim HY, Jadhav VB, Jeong DY, Park WK, Song JH, Lee S, Cho H.

Arch Pharm Res. 2015 Jun;38(6):1019-32. doi: 10.1007/s12272-015-0560-4. Epub 2015 Jan 20.

PMID:
25599616
9.

Langerhans cells release prostaglandin D2 in response to nicotinic acid.

Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT.

J Invest Dermatol. 2006 Dec;126(12):2637-46. Epub 2006 Sep 28.

10.

Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.

Carballo-Jane E, Gerckens LS, Luell S, Parlapiano AS, Wolff M, Colletti SL, Tata JR, Taggart AK, Waters MG, Richman JG, McCann ME, Forrest MJ.

J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):308-16. Epub 2007 Jun 23.

PMID:
17643322
11.

Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.

Ingersoll MA, Potteaux S, Alvarez D, Hutchison SB, van Rooijen N, Randolph GJ.

Immunobiology. 2012 May;217(5):548-57. doi: 10.1016/j.imbio.2011.05.014. Epub 2011 May 30.

12.

GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.

Imbriglio JE, Chang S, Liang R, Raghavan S, Schmidt D, Smenton A, Tria S, Schrader TO, Jung JK, Esser C, Holt TG, Wolff MS, Taggart AK, Cheng K, Carballo-Jane E, Waters MG, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4. doi: 10.1016/j.bmcl.2010.06.041. Epub 2010 Jun 10.

PMID:
20615702
13.

Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.

Lukasova M, Malaval C, Gille A, Kero J, Offermanns S.

J Clin Invest. 2011 Mar;121(3):1163-73. doi: 10.1172/JCI41651. Epub 2011 Feb 7.

14.
15.

Nicotinic acid: recent developments.

Kamanna VS, Vo A, Kashyap ML.

Curr Opin Cardiol. 2008 Jul;23(4):393-8. doi: 10.1097/HCO.0b013e3283021c82. Review.

PMID:
18520725
16.

Recent advances in niacin and lipid metabolism.

Kamanna VS, Ganji SH, Kashyap ML.

Curr Opin Lipidol. 2013 Jun;24(3):239-45. doi: 10.1097/MOL.0b013e3283613a68. Review.

PMID:
23619367
17.

Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.

Li X, Millar JS, Brownell N, Briand F, Rader DJ.

Biochem Pharmacol. 2010 Nov 1;80(9):1450-7. doi: 10.1016/j.bcp.2010.07.023. Epub 2010 Jul 22.

18.

Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets.

Chen L, So WY, Li SY, Cheng Q, Boucher BJ, Leung PS.

Mol Cell Endocrinol. 2015 Mar 15;404:56-66. doi: 10.1016/j.mce.2015.01.029. Epub 2015 Jan 23.

PMID:
25622782
19.

It ain't over 'til the fat lady sings.

Offermanns S.

Sci Transl Med. 2012 Aug 22;4(148):148fs30. doi: 10.1126/scitranslmed.3004445.

PMID:
22914620
20.

Supplemental Content

Support Center